<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02452268</url>
  </required_header>
  <id_info>
    <org_study_id>CNIZ985X2102J</org_study_id>
    <secondary_id>NIZ985X2102J</secondary_id>
    <nct_id>NCT02452268</nct_id>
  </id_info>
  <brief_title>A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers</brief_title>
  <official_title>A Phase 1 Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Ra)) Alone and in Combination With PDR001 in Adults With Metastatic Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I/Ib multicenter clinical trial. Single agent dose escalation of NIZ985 followed by&#xD;
      expansion. Second escalation of NIZ985 in combination with PDR001 followed by expansion&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 8, 2017</start_date>
  <completion_date type="Anticipated">January 6, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 6, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the dose-limiting toxicity of the single agent NIZ985 and the combination of PDR001</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the maximum tolerated dose (MTD) of hetIL-15 as determined by DLTs during Cycle 1.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the pharmacokinetic (PK) profile of hetIL-15, including T½</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the pharmacokinetic (PK) profile of hetIL-15, including Cmax.</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the preliminary anti-tumor activity of hetIL-15</measure>
    <time_frame>8 weeks</time_frame>
    <description>Best overall response (BOR) per RECIST and irRC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Metastatic and Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>NIZ985</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single treatment arm, dose escalation administered subcutaneously (SC) on MWF for 2 consecutive weeks.&#xD;
Cycle length 28 days.&#xD;
Occurrence of a dose-limiting toxicity (DLT) leads to the expansion to 6 subjects.&#xD;
MTD is the dose prior to the dose level where ≥ 2/6 subjects have a DLT.&#xD;
Following identification of the MTD / RDE, dose expansion will follow.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIZ985 + PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The phase Ib dose escalation portion of the study will consist of a fixed dose (400 mg, IV infusion, Q4W) of PDR001 and escalating doses of NIZ985 (hetIL-15) to evaluate safety, tolerability and determine the MTD and/or RDE of the combination to be used in expansion cohorts.&#xD;
On days when PDR001 and NIZ985 are administered on the same day, PDR001 will be administered first. NIZ985 will be administered after the PDR001 infusion has been completed.&#xD;
Information on the preparation and administration of PDR001 is found in the PDR001 pharmacy manual.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NIZ985</intervention_name>
    <description>Subcutaneous administration of hetIL-15 three times a week for two consecutive weeks</description>
    <arm_group_label>NIZ985</arm_group_label>
    <other_name>IL-15/sIL-15Ra, heterodimeric IL-15</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>• PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle</description>
    <arm_group_label>NIZ985 + PDR001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed solid tumor malignancy that is metastatic or unresectable and&#xD;
             have progressed on at least 1 prior therapy and for whom standard curative or&#xD;
             palliative measures do not exist or are associated with minimal subject survival&#xD;
             benefit.&#xD;
&#xD;
             Evaluable or measurable disease, defined as by Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST).&#xD;
&#xD;
          2. Recovered to ≤ grade 1 NCI CTCAE version 4.0 from toxicity of prior chemotherapy or&#xD;
             biologic therapy administered more than 4 weeks earlier.&#xD;
&#xD;
          3. Subjects on bisphosphonates for any cancer or on hormone therapy for prostate cancer&#xD;
             may continue this therapy. However, subjects with prostate cancer must have confirmed&#xD;
             metastatic disease that has progressed despite hormonal therapy producing castrate&#xD;
             levels of testosterone.&#xD;
&#xD;
          4. Age ≥18 years.&#xD;
&#xD;
          5. ECOG performance status ≤1 (Karnofsky ≥70%).&#xD;
&#xD;
          6. Normal organ and marrow function:&#xD;
&#xD;
               -  leukocytes ≥3,000/mcL&#xD;
&#xD;
               -  absolute neutrophil count (ANC) ≥1,500/mcL&#xD;
&#xD;
               -  platelets ≥100,000/mcL&#xD;
&#xD;
               -  total bilirubin within normal institutional limits&#xD;
&#xD;
               -  AST/ALT ≤2.5 × ULN&#xD;
&#xD;
               -  creatinine &lt;1.5 × institutional ULN OR&#xD;
&#xD;
               -  creatinine clearance ≥60 mL/min/1.73 m2 for subjects with serum creatinine levels&#xD;
                  &gt;1.5 × higher than ULN.&#xD;
&#xD;
          7. DLCO/VA and FEV1 ≥ 50% of predicted on PFTs.&#xD;
&#xD;
          8. Subjects with inactive central nervous system (CNS) metastasis are eligible..&#xD;
&#xD;
          9. Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             prior to study entry, during the treatment portion of the study and for 4 months after&#xD;
             completion of hetIL-15 administration.&#xD;
&#xD;
         10. Able to provide written informed consent.&#xD;
&#xD;
         11. Life expectancy &gt; 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior IL-15 treatment or cytotoxic therapy, immunotherapy, radiotherapy, major&#xD;
             surgery, antitumor vaccines or monoclonal antibodies in the 4 weeks prior or for&#xD;
             checkpoint inhibitors such as anti-CTLA-4 or anti PD1/PD-L1 or nitrosoureas or&#xD;
             mitomycin C for 6 weeks prior to C1D1.&#xD;
&#xD;
          2. Primary brain cancers or active CNS metastases should be excluded from this clinical&#xD;
             trial&#xD;
&#xD;
          3. History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to hetIL-15.&#xD;
&#xD;
          4. Concurrent anticancer therapy (including other investigational agents) with the&#xD;
             exception of hormone therapy for prostate cancer.&#xD;
&#xD;
          5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, cognitive impairment, active substance abuse, or psychiatric&#xD;
             illness/social situations that, in the view of the Investigator, would preclude safe&#xD;
             treatment or the ability to give informed consent and limit compliance with study&#xD;
             requirements.&#xD;
&#xD;
          6. HIV positive patients.&#xD;
&#xD;
          7. Positive hepatitis B or C serology.&#xD;
&#xD;
          8. History of severe asthma or absolute requirement for chronic inhaled corticosteroid&#xD;
             medications.&#xD;
&#xD;
          9. History of autoimmune disease, with the exception of an autoimmune event associated&#xD;
             with prior ipilimumab (anti-CTLA-4) therapy that has been completely resolved for more&#xD;
             than 4 weeks prior to C1D1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Institute National Cancer Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine SC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center SC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>May 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2015</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spartalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

